MEK

Mitogen-activated protein kinase kinase; MAPKK; MAP2K

MEK

MEK Isoform Specific Products:

MEK Isoform Comparison

MEK Related Products (139)
Antibodies (9)
MEK Isoform Comparison

By Effects:	Inhibitors (127) Degrader (1) Antagonists (2) Activator (1)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-10254G

Mirdametinib (GMP)	Inhibitor
Mirdametinib (PD0325901) (GMP) is Mirdametinib (HY-10254) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mirdametinib is an orally active, selective and non-ATP-competitive MEK inhibitor.

HY-107621

U0124		≥98.0%
U0124, an inactive U0126 analog, has no effect on c-Fos and c-Jun protein or mRNA levels. U0126 is a MEK inhibitor. U0124 does not inhibit MEK at concentrations up to 100 μM.

HY-153445

MEK-IN-6	Inhibitor	98.69%
MEK-IN-6 (Example 69) is a MEK inhibitor. MEK-IN-6 inhibits ERK1/2 (Thr202/Tyr204) phosphorylation in A375 cells (IC₅₀: 2 nM). MEK-IN-6 can be used for research of cancer.

HY-131295

PD0325901-O-C2-dioxolane	Inhibitor	98.62%
PD0325901-O-C2-dioxolane has main portion of MEK inhibitor PD0325901. PD0325901-O-C2-dioxolane and a ligand of VHL or CRBN E3 ligase can be used in the synthesis of MEK1/2 degrader.

HY-107619

PD-334581	Inhibitor	99.72%
PD-334581 is a MEK1 inhibitor.

HY-107417

Hypothemycin	Inhibitor	≥98.0%
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for VEGFR2/KDR/Flk-1/VEGFR1/Flt-1, MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2, respectively.

HY-142042

3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles	Inhibitor	99.84%
3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles is an inhibitor for bone morphogenetic protein 2 (BMP2) with an IC₅₀ of 2.2 μM. 3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles is inhibitor for mitogen-activated protein kinase 1 (MEK1). 3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles exhibits anti-inflammatory and neuroprotective activity in EAE mouse model.

HY-B0185AS

Lidocaine-d₁₀ hydrochloride	Inhibitor	99.79%
Lidocaine-d₁₀ (hydrochloride) is the deuterium labeled Lidocaine hydrochloride. Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride, an amide derivative, has the potential for the research of the ventricular arrhythmia[2].

HY-15496

E6201	Inhibitor
E6201 (ER-806201) is an ATP-competitive dual kinase inhibitor of MEK1 and FLT3. E6201 inhibits MEK1- induced ERK2 phosphorylation with an IC₅₀ value of 5.2 nM, MKK4-induced JNK phosphorylation with an IC₅₀ value of 91 nM, and MKK6-induced p38 MAPK phosphorylation with an IC₅₀ value of 19 nM. Anti-tumor and anti-psoriasis efficacy.

HY-B0185S1

Lidocaine-d₁₀	Inhibitor	98.89%
Lidocaine-d₁₀ is the deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia[2].

HY-10216

Refametinib (R enantiomer)	Inhibitor
Refametinib R enantiomer is a MEK inhibitor extracted from patent WO2007014011A2, compound 1022, has an EC₅₀ of 2.0-15 nM.

HY-14947

Balamapimod	Inhibitor	99.47%
Balamapimod (MKI 833) is a reversible Ras/Raf/MEK inhibitor with potential anti-tumor activity.

HY-N0811

Anemarsaponin B	Inhibitor
Anemarsaponin B is a steroidal saponin. Anemarsaponin B decreases the protein and mRNA levels of iNOS and COX-2. Anemarsaponin B reduces the expressions and productions of pro-inflammatory cytokines, including TNF-a and IL-6. Anemarsaponin B inhibits the nuclear translocation of the p65 subunit of NF-κB by blocking the phosphorylation of IκBα. Anemarsaponin B also inhibits the phosphorylation of MAP kinase kinases 3/6 (MKK3/6) and mixed lineage kinase 3 (MLK3). Anti-inflammatory effect .

HY-160414

TRX-COBI	Inhibitor
TRX-COBI ((R,R)-TRX-COBI; Trx-cobimetinib) is a MEK inhibitor targeting TRX fragments based on Fe²⁺. TRX-COBI has antitumor activity.

HY-139638

MEK4 inhibitor-1	Inhibitor	98.89%
MEK4 inhibitor-1 is a novel MEK4 inhibitor against pancreatic adenocarcinoma with an IC₅₀ value of 61 nM.

HY-101522

CHMFL-EGFR-202	Inhibitor	99.75%
CHMFL-EGFR-202 is a potent, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant kinase, with IC₅₀s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively. CHMFL-EGFR-202 exhibits ～10-fold selectivity for EGFR L858R/T790M against the EGFR wild-type in cells. CHMFL-EGFR-202 adopts a covalent “DFG-in-C-helix-out” inactive binding conformation with EGFR, with strong antiproliferative effects against EGFR mutant-driven nonsmall-cell lung cancer (NSCLC) cell lines.

HY-B0185G

Lidocaine (GMP)	Inhibitor
Lidocaine (GMP) is Lidocaine (HY-B0185) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Lidocaine inhibits sodium channels involving complex voltage and using dependence. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia.

HY-10999R

Trametinib (Standard)	Inhibitor
Trametinib (Standard) is the analytical standard of Trametinib. This product is intended for research and analytical applications. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib activates autophagy and induces apoptosis.

HY-N12740

Napyradiomycin B4	Inhibitor
Napyradiomycin B4 is a Napyradiomycin derivative, which inhibits the RANKL-induced MEK-ERK signaling pathway. Napyradiomycin B4 attenuates osteoclastogenesis and prevents alveolar bone destruction in experimental periodontitis.

HY-100627A

APS-2-79 hydrochloride	Antagonist
APS-2-79 hydrochloride is a KSR-dependent MEK antagonist. APS-2-79 inhibits ATP^biotin binding to KSR2 within the KSR2-MEK1 complexe with an IC₅₀ of 120 nM. APS-2-79 makes the stabilization of the KSR inactive state antagonizes oncogenic Ras-MAPK signaling.

Trametinib	MEK1, IC₅₀: 2 nM	MEK2, IC₅₀: 2 nM			99.96%
Mirdametinib	MEK1, Ki: 1 nM	MEK2, Ki: 1 nM		MEK, IC₅₀: 0.33 nM	99.95%
PD98059	MEK1, IC₅₀: 2-7 μM	MEK2, IC₅₀: 50 μM			99.96%
U0126	MEK1, IC₅₀: 70 nM	MEK2, IC₅₀: 60 nM			98.45%
Selumetinib	MEK1, IC₅₀: 14 nM			MEK, IC₅₀: 12 nM	99.87%
TERT activator-1	MEK1	MEK2			99.50%
U0126-EtOH	MEK1, IC₅₀: 70 nM	MEK2, IC₅₀: 60 nM			99.41%
Cobimetinib	MEK1, IC₅₀: 4.2 nM				99.81%
Binimetinib				MEK, IC₅₀: 12 nM	99.28%
C16-PAF				MEK	99.85%
Isorhamnetin	MEK1				99.94%
Avutometinib				MEK, IC₅₀: 160 nM	99.02%
Lidocaine				MEK	99.96%
Trametinib (DMSO solvate)	MEK1, IC₅₀: 2 nM	MEK2, IC₅₀: 2 nM			99.56%
trans-Zeatin				MEK	99.83%
CI-1040	MEK1, IC₅₀: 17 nM				99.91%
Pimasertib	MEK1	MEK2			99.88%
GDC-0623	MEK1, Ki: 0.13 nM (+ATP)				98.74%
Lixisenatide	MEK1	MEK2			99.93%
BIX02189			MEK5, IC₅₀: 1.5 nM		99.99%
Lidocaine hydrochloride				MEK	99.96%
Trametiglue	MEK1	MEK2			98.58%
Refametinib	MEK1, IC₅₀: 19 nM	MEK2, IC₅₀: 47 nM			99.82%
TAK-733				MEK, IC₅₀: 3.2 nM	98.31%
AZD8330	MEK1, IC₅₀: 7 nM	MEK2, IC₅₀: 7 nM			99.14%
APS-2-79	MEK1				99.38%
MS432	MEK1, DC₅₀: 31 nM (in HT29 cells) MEK1, DC₅₀: 31 nM (in SK-MEL-28 cells)	MEK2, DC₅₀: 17 nM (in HT29 cells) MEK2, DC₅₀: 9.3 nM (in SK-MEL-28 cells)			99.78%
Lidocaine (Standard)				MEK	99.85%
SL327	MEK1, IC₅₀: 180 nM	MEK2, IC₅₀: 220 nM			99.57%
RGB-286638	MEK1, IC₅₀: 54 nM				99.70%
Azelnidipine	MEK1	MEK2			99.66%
MAP855	MEK1, IC₅₀: 3 nM				98.48%
BI-847325		MEK2, IC₅₀: 4 nM			98.15%
Tunlametinib	MEK1	MEK2			98.25%
RO4987655	MEK1, IC₅₀: 5.2 nM	MEK2, IC₅₀: 5.2 nM			99.26%
GW284543			MEK5		99.94%
Zapnometinib				MEK, IC₅₀: 5.7 nM	99.85%
BIX02188			MEK5, IC₅₀: 4.3 nM		99.85%
PD318088	MEK1	MEK2			99.91%
Cobimetinib hemifumarate	MEK1, IC₅₀: 4.2 nM				99.73%
RGB-286638 free base	MEK1, IC₅₀: 54 nM				98.07%
PD 198306				MEK	99.75%
MEK inhibitor				MEK	98.35%
PD184161				MEK, IC₅₀: 10-100 nM	98.08%
Lidocaine hydrochloride hydrate				MEK	99.90%
MEK-IN-6				MEK	98.69%
PD0325901-O-C2-dioxolane	MEK1	MEK2			98.62%
PD-334581	MEK1				99.72%
Hypothemycin	MEK1, Ki: 17 nM	MEK2, Ki: 38 nM			≥98.0%
E6201	MEK1, IC₅₀: 5.2 nM
Refametinib (R enantiomer)				MEK, EC₅₀: 2-15 nM
Balamapimod				MEK	99.47%
CHMFL-EGFR-202	MEK1, IC₅₀: 161 nM				99.75%
APS-2-79 hydrochloride	MEK1
GW284543 hydrochloride			MEK5
MEK/RAF-IN-1	MEK1, IC₅₀: 28 nM
MEK/PI3K-IN-2	MEK1, IC₅₀: 352 ± 2 nM
MEK/PI3K-IN-1	MEK1, IC₅₀: 124 ± 11 nM
Isorhamnetin (Standard)	MEK1
MEK1-IN-1	MEK1, : 10.29 nM
MEK-IN-6 hydrate				MEK
MEK-IN-1				MEK

Name
Email *

	Sorry, but the email address you supplied was invalid.

MEK

MEK

MEK Isoform Specific Products:

MEK Isoform Specific Products:

MEK Related Products (139)

Antibodies (9)

MEK Isoform Comparison

MEK Related Products (139):